Addressing nephrotoxicity in agents commonly used to treat multiple myeloma
Nelson Leung • 28 Sep 2023
A RESPONSE to ruxolitinib: update on 4-year trial follow-up
Jean-Jacques Kiladjian • 2 Mar 2018
Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.